These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 31073561)

  • 41. Protein interaction screening by quantitative immunoprecipitation combined with knockdown (QUICK).
    Selbach M; Mann M
    Nat Methods; 2006 Dec; 3(12):981-3. PubMed ID: 17072306
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effects of miR-143 overexpression on proliferation, apoptosis, EGFR and downstream signaling pathways in PC9/GR cell line.
    Dong YZ; Hu T
    Eur Rev Med Pharmacol Sci; 2018 Mar; 22(6):1709-1716. PubMed ID: 29630116
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Chemoresistant tumor cell lines display altered epidermal growth factor receptor and HER3 signaling and enhanced sensitivity to gefitinib.
    Servidei T; Riccardi A; Mozzetti S; Ferlini C; Riccardi R
    Int J Cancer; 2008 Dec; 123(12):2939-49. PubMed ID: 18803287
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Estrogen receptor β1 activation accelerates resistance to epidermal growth factor receptor-tyrosine kinase inhibitors in non-small cell lung cancer.
    Fu S; Liu C; Huang Q; Fan S; Tang H; Fu X; Ai B; Liao Y; Chu Q
    Oncol Rep; 2018 Mar; 39(3):1313-1321. PubMed ID: 29328407
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Co-immunoprecipitation for Identifying Protein-Protein Interactions in Borrelia burgdorferi.
    Iqbal H; Akins DR; Kenedy MR
    Methods Mol Biol; 2018; 1690():47-55. PubMed ID: 29032535
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Exploring Protein⁻Protein Interaction in the Study of Hormone-Dependent Cancers.
    Miki Y; Iwabuchi E; Ono K; Sasano H; Ito K
    Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30326622
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The impact of intermittent versus continuous exposure to EGFR tyrosine kinase inhibitor on selection of EGFR T790M-mutant drug-resistant clones in a lung cancer cell line carrying activating EGFR mutation.
    Lee Y; Choi YR; Kim KY; Shin DH
    Oncotarget; 2016 Jul; 7(28):43315-43323. PubMed ID: 27270313
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Co-immunoprecipitation and protein blots.
    Isono E; Schwechheimer C
    Methods Mol Biol; 2010; 655():377-87. PubMed ID: 20734274
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Multi-paratopic VEGF decoy receptor have superior anti-tumor effects through anti-EGFRs and targeted anti-angiogenic activities.
    Lee DH; Lee MY; Seo Y; Hong HJ; An HJ; Kang JS; Kim HM
    Biomaterials; 2018 Jul; 171():34-45. PubMed ID: 29679794
    [TBL] [Abstract][Full Text] [Related]  

  • 50. PGE2/EP3/SRC signaling induces EGFR nuclear translocation and growth through EGFR ligands release in lung adenocarcinoma cells.
    Bazzani L; Donnini S; Finetti F; Christofori G; Ziche M
    Oncotarget; 2017 May; 8(19):31270-31287. PubMed ID: 28415726
    [TBL] [Abstract][Full Text] [Related]  

  • 51. ErbB receptors mediate both migratory and proliferative activities in human melanocytes and melanoma cells.
    Gordon-Thomson C; Jones J; Mason RS; Moore GP
    Melanoma Res; 2005 Feb; 15(1):21-8. PubMed ID: 15714117
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Label-Free Immunoprecipitation Mass Spectrometry Workflow for Large-scale Nuclear Interactome Profiling.
    Guard SE; Ebmeier CC; Old WM
    J Vis Exp; 2019 Nov; (153):. PubMed ID: 31789314
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Understanding EGFR Signaling in Breast Cancer and Breast Cancer Stem Cells: Overexpression and Therapeutic Implications.
    Alanazi IO; Khan Z
    Asian Pac J Cancer Prev; 2016; 17(2):445-53. PubMed ID: 26925626
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Label-free imaging of epidermal growth factor receptor-induced response in single living cells.
    Peng Z; Lu J; Zhang L; Liu Y; Li J
    Analyst; 2018 Nov; 143(21):5264-5270. PubMed ID: 30280173
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Profiling Signaling Proteins in Sertoli Cells by Co-immunoprecipitation.
    Freitas MJ; Fardilha M
    Methods Mol Biol; 2018; 1748():73-84. PubMed ID: 29453566
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Co-immunoprecipitation for Deciphering Protein Interactomes.
    Smith BJ; Cassoli JS; Guest PC; Martins-de-Souza D
    Adv Exp Med Biol; 2017; 974():229-236. PubMed ID: 28353240
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cross-talk between AMPK and EGFR dependent Signaling in Non-Small Cell Lung Cancer.
    Praveen P; Hülsmann H; Sültmann H; Kuner R; Fröhlich H
    Sci Rep; 2016 Jun; 6():27514. PubMed ID: 27279498
    [TBL] [Abstract][Full Text] [Related]  

  • 58. CHIP-MYTH: a novel interactive proteomics method for the assessment of agonist-dependent interactions of the human β₂-adrenergic receptor.
    Kittanakom S; Barrios-Rodiles M; Petschnigg J; Arnoldo A; Wong V; Kotlyar M; Heisler LE; Jurisica I; Wrana JL; Nislow C; Stagljar I
    Biochem Biophys Res Commun; 2014 Mar; 445(4):746-56. PubMed ID: 24561123
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Identification of protein expression alterations in gefitinib-resistant human lung adenocarcinoma: PCNT and mPR play key roles in the development of gefitinib-associated resistance.
    Lin CC; Chen JT; Lin MW; Chan CH; Wen YF; Wu SB; Chung TW; Lyu KW; Chou HC; Chan HL
    Toxicol Appl Pharmacol; 2015 Nov; 288(3):359-73. PubMed ID: 26298006
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effects of Src inhibitors on cell growth and epidermal growth factor receptor and MET signaling in gefitinib-resistant non-small cell lung cancer cells with acquired MET amplification.
    Yoshida T; Okamoto I; Okamoto W; Hatashita E; Yamada Y; Kuwata K; Nishio K; Fukuoka M; Jänne PA; Nakagawa K
    Cancer Sci; 2010 Jan; 101(1):167-72. PubMed ID: 19804422
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.